Mississippi

1. 1What the law is

If the FDA ever approves a psilocybin medicine, Mississippi has already written what happens next. SB 2056 (Chapter 322, 2026) is a trigger law: pharmaceutical psilocybin is scheduled for medical use in the state only once the FDA approves it and the DEA reschedules it federally. The other 2026 enactment, the Ibogaine Drug Development Clinical Trial Act (HB 314, Chapter 424), funds FDA clinical trials of ibogaine and nothing else. Psilocybin is Schedule I here, with no access program.

Is psilocybin legal in Mississippi? No. Psilocybin is a Schedule I controlled substance under the Mississippi Uniform Controlled Substances Law (Miss. Code Ann. § 41-29-113), and the state operates no medical, therapeutic, or decriminalized-possession program for it. Possession, sale, and cultivation are criminal offenses prosecuted under the state controlled-substances code. Two 2026 enactments touch adjacent ground, but neither legalizes psilocybin or creates any current path to lawful access.

Psilocybin remains illegal in Mississippi today; the 2026 legislative session produced no change to its status. In that session the Legislature enacted the Ibogaine Drug Development Clinical Trial Act (HB 314, Chapter 424), signed March 26, 2026 and effective July 1, 2026, which directs the State Department of Health to fund FDA clinical trials of ibogaine, a different substance, and does not authorize psilocybin use of any kind. The Legislature also enacted SB 2056 (Chapter 322), signed March 13, 2026 and effective July 1, 2026, a trigger law that would schedule an FDA-approved pharmaceutical psilocybin polymorph for medical use only if and when the U.S. Food and Drug Administration approves it and the federal Drug Enforcement Administration reschedules it. Because that federal action has not occurred, SB 2056 confers no present legal access, and psilocybin remains a Schedule I substance under Mississippi law.

2. 2History

The legal events behind this entry, dated and oldest first. Our own reviews and corrections are listed under Changes to this record.

1. 2026
   13 Mar

   Governor signed SB 2056 (Chapter 322), a trigger law that would schedule FDA-approved pharmaceutical psilocybin for medical use only upon future federal rescheduling; effective July 1, 2026.

   26 Mar

   Governor signed HB 314 (Chapter 424), the Ibogaine Drug Development Clinical Trial Act, funding FDA trials of ibogaine only; effective July 1, 2026. It creates no psilocybin program.

   01 Jul

   Both HB 314 and SB 2056 took effect; psilocybin's Schedule I status under Mississippi law was unchanged.

3. 3Proposed laws

None. Every psilocybin or ibogaine measure filed in the 2026 Regular Session has reached a terminal action: HB 314 and SB 2056 were approved by the Governor as Chapters 424 and 322, HB 563 died on the Senate calendar on 03/11, and SB 2561 and SB 2562 died in committee on 02/03 (Mississippi Legislature, All Measures index for the 2026 Regular Session, checked 16 Aug 2026).

4. 4Common questions